MicroRNA‐26‐5p functions as a new inhibitor of hepatoblastoma by repressing lin‐28 homolog B and aurora kinase a expression

Yutong Zhang, Yulan Zhao, Jianguo Wu, Suthat Liangpunsakul, Junqi Niu, Li Wang – 21 May 2018 – Hepatoblastoma (HB) is the most common liver tumor in children. Despite recent improvements in treatment strategies, the survival of children with hepatoblastoma remains poor. In this study, we identified a novel role of microRNA‐26a‐5p (miR‐26a‐5p), lin‐28 homolog B (LIN28B), Ras‐related nuclear protein (RAN), and aurora kinase A (AURKA) in HB. The expression of LIN28B, RAN, and AURKA was significantly up‐regulated in human HB livers and cell lines.

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

Derek J. Erstad, Christian T. Farrar, Sarani Ghoshal, Ricard Masia, Diego S. Ferreira, Yin‐Ching Iris Chen, Ji‐Kyung Choi, Lan Wei, Phillip A. Waghorn, Nicholas J. Rotile, Chuantao Tu, Katherine A. Graham‐O'Regan, Mozhdeh Sojoodi, Shen Li, Yang Li, Guogiang Wang, Kathleen E. Corey, Yat Sun Or, Lijuan Jiang, Kenneth K. Tanabe, Peter Caravan, Bryan C. Fuchs – 21 May 2018 – We examined a novel farnesoid X receptor agonist, EDP‐305, for its antifibrotic effect in bile duct ligation (BDL) and choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) models of hepatic injury.

Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma

Mariya L. Samoylova, Neil Mehta, John P. Roberts, Francis Y. Yao – 21 May 2018 – Current guidelines recommend ultrasound (US) for hepatocellular carcinoma (HCC) surveillance in cirrhosis. We assess predictors of decreased US sensitivity for detecting HCC. At a single center in the United States, all HCC patients evaluated for liver transplantation (LT) received an abdominal US. From 2007‐2015, consecutive patients presenting for untreated lesions found on computed tomography (CT) or magnetic resonance imaging (MRI) within 3 months of US were compared with US findings.

Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real‐World Data From a Large U.S. Claims Database

Alina M. Allen, Holly K. Houten, Lindsey R. Sangaralingham, Jayant A. Talwalkar, Rozalina G. McCoy – 18 May 2018 – The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing. The health care burden resulting from the multidisciplinary management of this complex disease is unknown. We assessed the total health care cost and resource utilization associated with a new NAFLD diagnosis, compared with controls with similar comorbidities.

Subscribe to